Back to resultsA Prospective Study Investigating the Effects of a Novel Weight Management Program
Primary Purpose
Overweight
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dietary Supplements and TR90 Eating Plan
Placebo and Low Fat Eating Plan
Sponsored by
About this trial
This is an interventional treatment trial for Overweight
Eligibility Criteria
Inclusion Criteria:
- Male or female 18-65 years of age at the time of informed consent
- The ability to read, speak and understand the English language in order to complete the required paper informed consent, assessments and diary
- Access to email and to a digital camera or camera phone
- Willing and able to provide written informed consent
- Willing and able to comply with the study restrictions, procedures and assessments and attend regularly scheduled clinic visits
- Willing and able to accommodate being contacted by the study staff for telephone call visits, follow-up contacts, and study visit reminders
- BMI is equal to or greater than 25 and less than or equal to 40 kg/m2
- Use of effective method of contraception by females of childbearing potential 30-days before the screening visit and agree to continue to practice that acceptable method of contraception for the duration of her participation in the study
- A resting normotensive blood pressure, as defined as a systolic blood pressure between 150-90 mmHg and a diastolic blood pressure of between 95-50 mmHg, at screening visit 1(A)
- Willing to fast for at least 8 hours prior to the study procedures being performed that require fasting measurements
- Willing and able to follow eating program and able to consume the study supplied Supplements, Placebos and shakes (which include whey and/or egg protein) on a daily basis. Subjects that are lactose intolerant will be considered ineligible
- Only one member per household eligible to participate in the study
Exclusion Criteria:
- A subject that has any Axis I Psychiatric disorders according to the DSM-IV criteria that would prevent the subject from being able to comply with study requirements and/or taking anti-psychotic medication
- Diagnosed with insomnia and is chronically using prescribed or OTC insomnia medications
- A self-reported chronic condition that may affect subject safety
- An HbA1c of greater than or equal to 7.0%
- Renal insufficiency as defined by a laboratory Glomerular Filtration Rate of less than 50 mL/min/1.73 m2
- Chronically using glucocorticoid steroids
- Currently pregnant, planning to become pregnant during the course of the study or is breastfeeding
- Use of antihypertensive medication(s) for less than 90 days prior to screening
- Diagnosed with any thyroid disorder or has a clinically significant out of range laboratory value (i.e. TSH, T3 Free, and/or T4 Free) value measured at screening
- Known allergy or intolerance to any of the ingredients contained in the Novel Supplements, placebos or shakes (cow milk proteins)
- Planned surgical procedure during the 365 day course of the study
- Currently participating in another clinical research study or have done so within 30 days prior to the screening visit
- Diagnosis of milk or egg intolerance
- Participating in another weight loss program or using another weight loss product. Subjects may enroll if they are willing to stop the weight loss program they are currently on and/or washout of the product they are using. The appropriate washout will be reviewed with the investigator or medically qualified designee on a case by case basis
- Fasting LDL-C greater than 190 mg/dL or triglycerides greater than 400 mg/dL.
- Unwilling to discontinue consumption of green or black tea or green or black tea extracts beginning at the screening visit and after signing of the informed consent
- Unwilling to discontinue use of over-the-counter and/or prescribed vitamin supplements except for: multivitamins, calcium, fish oil, vitamin C, vitamin D, vitamin E, zinc or iron
- Plans to have plastic or reconstructive surgery or any other procedure that, in the opinion of the investigator, could influence body composition, at any time during the year long study
- Unable to lay supine for at least 30 minutes
- Cognitive impairment that would limit ability to understand or follow diet instructions and/or comply with the study protocol
Sites / Locations
- Utah State University
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo and Low Fat Eating Plan
Dietary Supplements and TR90 Eating Plan
Arm Description
Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal) The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals.
Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal) Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals.
Outcomes
Primary Outcome Measures
Determine the effect of a novel weight management program on body fat mass over 90 days.
Evaluate changes in body measurements (weight and BMI; arm, waist, hip, thigh, claf, and ankle circumferences) and body composition (fat mass, fat free mass, % body fat) by Dual Energy X-ray Absorptiometry (DEXA) scanner.
Secondary Outcome Measures
Determine the safety of novel weight management program (CBC, Comp. metabolic, lipid panel, heart rate, blood pressure and adverse events)
Evaluate changes in body measurements (weight and BMI; arm, waist, hip, thigh, claf, and ankle circumferences) and body composition (fat mass, fat free mass, % body fat) by Dual Energy X-ray Absorptiometry (DEXA) scanner.
Determine subjective measurements of hunger and appetite from standardized questionnaires (IWQOL Hunger/Appetite and overall wellbeing)
Determine skin carotenoid (Biophotonic Scanner) measurement changes.
Biophotonic Scanner utilizes raman spectroscopy to determine skin carotenoid concentrations.
Evaluate the changes in metabolism and appetite hormone levels from the baseline visit to day 90.
Leptin, Insulin, Adiponectin, Pancreatic Polypeptide, gLP1, C-peptide, Glucagon, Resistin and HbA1c
Evaluate the changes in inflammatory markers from the baseline visit to day 90.
hsCRP, IL-6 and TNF Receptors 60 and 80
Evaluate the changes in gene expression from the baseline visit to day 90.
Full gene arrays will be made on peripheral blood mononuclear cells. The gene expression changes will be made at baseline and day 90. There will also be a comparison back to proteins (i.e. hormones and inflammatory markers).
Evaluate resting energy expenditure and substrate utilization from baseline to days 90, 180, and 365.
Resting metabolic rate (RMR)and substrate utilization (R-values to determine wheather subjects are utilizing more fats or carbohydrates to meet energy demands) will be measured by CPET Quark.
Full Information
NCT ID
NCT01875354
First Posted
June 5, 2013
Last Updated
April 3, 2017
Sponsor
Pharmanex
Collaborators
Utah State University
1. Study Identification
Unique Protocol Identification Number
NCT01875354
Brief Title
A Prospective Study Investigating the Effects of a Novel Weight Management Program
Official Title
A Prospective, Randomized, Blinded, Controlled Study Investigating the Effects of a Novel Body Weight Management Program Over 90-days and Weight Maintenance at One Year.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
November 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pharmanex
Collaborators
Utah State University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to assess the safety and efficacy of a weight management program composed of dietary supplements and a reduced calorie eating program.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
141 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo and Low Fat Eating Plan
Arm Type
Placebo Comparator
Arm Description
Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)
The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals.
Arm Title
Dietary Supplements and TR90 Eating Plan
Arm Type
Experimental
Arm Description
Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)
Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals.
Intervention Type
Dietary Supplement
Intervention Name(s)
Dietary Supplements and TR90 Eating Plan
Intervention Description
Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo and Low Fat Eating Plan
Primary Outcome Measure Information:
Title
Determine the effect of a novel weight management program on body fat mass over 90 days.
Description
Evaluate changes in body measurements (weight and BMI; arm, waist, hip, thigh, claf, and ankle circumferences) and body composition (fat mass, fat free mass, % body fat) by Dual Energy X-ray Absorptiometry (DEXA) scanner.
Time Frame
Days 0 and 90
Secondary Outcome Measure Information:
Title
Determine the safety of novel weight management program (CBC, Comp. metabolic, lipid panel, heart rate, blood pressure and adverse events)
Time Frame
Throughout 1 year
Title
Evaluate changes in body measurements (weight and BMI; arm, waist, hip, thigh, claf, and ankle circumferences) and body composition (fat mass, fat free mass, % body fat) by Dual Energy X-ray Absorptiometry (DEXA) scanner.
Time Frame
throughout 1 year
Title
Determine subjective measurements of hunger and appetite from standardized questionnaires (IWQOL Hunger/Appetite and overall wellbeing)
Time Frame
Throughout 1 year
Title
Determine skin carotenoid (Biophotonic Scanner) measurement changes.
Description
Biophotonic Scanner utilizes raman spectroscopy to determine skin carotenoid concentrations.
Time Frame
Throughout 1 year
Title
Evaluate the changes in metabolism and appetite hormone levels from the baseline visit to day 90.
Description
Leptin, Insulin, Adiponectin, Pancreatic Polypeptide, gLP1, C-peptide, Glucagon, Resistin and HbA1c
Time Frame
Days 0 and 90
Title
Evaluate the changes in inflammatory markers from the baseline visit to day 90.
Description
hsCRP, IL-6 and TNF Receptors 60 and 80
Time Frame
Days 0 and 90
Title
Evaluate the changes in gene expression from the baseline visit to day 90.
Description
Full gene arrays will be made on peripheral blood mononuclear cells. The gene expression changes will be made at baseline and day 90. There will also be a comparison back to proteins (i.e. hormones and inflammatory markers).
Time Frame
Day 0 and 90
Title
Evaluate resting energy expenditure and substrate utilization from baseline to days 90, 180, and 365.
Description
Resting metabolic rate (RMR)and substrate utilization (R-values to determine wheather subjects are utilizing more fats or carbohydrates to meet energy demands) will be measured by CPET Quark.
Time Frame
Days 0, 90, 80, and 365
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male or female 18-65 years of age at the time of informed consent
The ability to read, speak and understand the English language in order to complete the required paper informed consent, assessments and diary
Access to email and to a digital camera or camera phone
Willing and able to provide written informed consent
Willing and able to comply with the study restrictions, procedures and assessments and attend regularly scheduled clinic visits
Willing and able to accommodate being contacted by the study staff for telephone call visits, follow-up contacts, and study visit reminders
BMI is equal to or greater than 25 and less than or equal to 40 kg/m2
Use of effective method of contraception by females of childbearing potential 30-days before the screening visit and agree to continue to practice that acceptable method of contraception for the duration of her participation in the study
A resting normotensive blood pressure, as defined as a systolic blood pressure between 150-90 mmHg and a diastolic blood pressure of between 95-50 mmHg, at screening visit 1(A)
Willing to fast for at least 8 hours prior to the study procedures being performed that require fasting measurements
Willing and able to follow eating program and able to consume the study supplied Supplements, Placebos and shakes (which include whey and/or egg protein) on a daily basis. Subjects that are lactose intolerant will be considered ineligible
Only one member per household eligible to participate in the study
Exclusion Criteria:
A subject that has any Axis I Psychiatric disorders according to the DSM-IV criteria that would prevent the subject from being able to comply with study requirements and/or taking anti-psychotic medication
Diagnosed with insomnia and is chronically using prescribed or OTC insomnia medications
A self-reported chronic condition that may affect subject safety
An HbA1c of greater than or equal to 7.0%
Renal insufficiency as defined by a laboratory Glomerular Filtration Rate of less than 50 mL/min/1.73 m2
Chronically using glucocorticoid steroids
Currently pregnant, planning to become pregnant during the course of the study or is breastfeeding
Use of antihypertensive medication(s) for less than 90 days prior to screening
Diagnosed with any thyroid disorder or has a clinically significant out of range laboratory value (i.e. TSH, T3 Free, and/or T4 Free) value measured at screening
Known allergy or intolerance to any of the ingredients contained in the Novel Supplements, placebos or shakes (cow milk proteins)
Planned surgical procedure during the 365 day course of the study
Currently participating in another clinical research study or have done so within 30 days prior to the screening visit
Diagnosis of milk or egg intolerance
Participating in another weight loss program or using another weight loss product. Subjects may enroll if they are willing to stop the weight loss program they are currently on and/or washout of the product they are using. The appropriate washout will be reviewed with the investigator or medically qualified designee on a case by case basis
Fasting LDL-C greater than 190 mg/dL or triglycerides greater than 400 mg/dL.
Unwilling to discontinue consumption of green or black tea or green or black tea extracts beginning at the screening visit and after signing of the informed consent
Unwilling to discontinue use of over-the-counter and/or prescribed vitamin supplements except for: multivitamins, calcium, fish oil, vitamin C, vitamin D, vitamin E, zinc or iron
Plans to have plastic or reconstructive surgery or any other procedure that, in the opinion of the investigator, could influence body composition, at any time during the year long study
Unable to lay supine for at least 30 minutes
Cognitive impairment that would limit ability to understand or follow diet instructions and/or comply with the study protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Lefevre, PhD
Organizational Affiliation
Utah State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Utah State University
City
Logan
State/Province
Utah
ZIP/Postal Code
84322
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Prospective Study Investigating the Effects of a Novel Weight Management Program
We'll reach out to this number within 24 hrs